Data gathered: November 27
Alternative Data for Lumos Pharma
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 5,072 | Sign up | Sign up | Sign up |
| Twitter Mentions | 11 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Lumos Pharma
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of rare disease therapies. The company is headquartered in Austin, Texas.
| Price | $4.30 |
| Target Price | Sign up |
| Volume | 102,130 |
| Market Cap | $37M |
| Year Range | $1.45 - $4.45 |
| Dividend Yield | 0% |
| Analyst Rating | 33% buy |
| Industry | Biotechnology |
In the news
$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues to Investigate the Mergers of OB, LUMO, PIK and PORTNovember 15 - GlobeNewswire |
|
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Lumos Pharma Inc. – LUMONovember 6 - GlobeNewswire |
|
 |
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024October 30 - Yahoo |
 |
FY2024 EPS Estimates for Lumos Pharma Boosted by AnalystOctober 28 - ETF Daily News |
|
Lumos Pharma’s (LUMO) “Neutral” Rating Reiterated at HC WainwrightOctober 26 - ETF Daily News |
Kuehn Law Encourages MMLP, ICCH, FSHP, and LUMO Investors to Contact Law FirmOctober 24 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 730,000 | 4.2M | -3.5M | -7.5M | -7.6M | -0.900 |
| Q2 '24 | 490,000 | 3.7M | -3.2M | -7.6M | -7.8M | -0.930 |
| Q1 '24 | 170,000 | 3.8M | -3.6M | -10M | -11M | -1.290 |
| Q4 '23 | 830,000 | 4.2M | -3.3M | -9.5M | -10M | -1.170 |
| Q3 '23 | 7,000 | 3.9M | -3.9M | -8.3M | -8.9M | -1.040 |
Insider Transactions View All
| McKew John C. filed to sell 12,653 shares at $1.9. August 6 '24 |
| McKew John C. filed to sell 17,153 shares at $2.8. April 3 '24 |
| McKew John C. filed to sell 18,403 shares at $3. February 7 '24 |
| McKew John C. filed to sell 18,707 shares at $3.2. August 3 '23 |
| McKew John C. filed to sell 23,207 shares at $3.3. April 4 '23 |
Similar companies
Read more about Lumos Pharma (LUMO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Lumos Pharma?
The Market Cap of Lumos Pharma is $37M.
What is the current stock price of Lumos Pharma?
Currently, the price of one share of Lumos Pharma stock is $4.30.
How can I analyze the LUMO stock price chart for investment decisions?
The LUMO stock price chart above provides a comprehensive visual representation of Lumos Pharma's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Lumos Pharma shares. Our platform offers an up-to-date LUMO stock price chart, along with technical data analysis and alternative data insights.
Does LUMO offer dividends to its shareholders?
As of our latest update, Lumos Pharma (LUMO) does not offer dividends to its shareholders. Investors interested in Lumos Pharma should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Lumos Pharma?
Some of the similar stocks of Lumos Pharma are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.